Long-acting insulin analogues have been shown to provide consistent glycaemic control with a lower incidence of hypoglycaemia compared with conventional insulin treatment with neutral protamine Hagedorn (NPH) insulin (7–10). The gene discussed is INS; the disease is Hypoglycemia.